Roth Capital affirms Cytokinetics (Nasdaq: CYTK) with a Buy rating and $18 price target after the company and Amgen (Nasdaq ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Amgen (AMGN) Sees Double-Digit EPS Growth Out to 2018; UBS Raises Price target to $180 October 29, 2015 10:46 AM Form 8-K CYTOKINETICS INC For: Oct 27October 27, 2015 8:02 AM Amgen (AMGN), Cytokinetics (CYTK) Announce Statistically Significant Data from COSMIC-HF Expansion StudyOctober 27, 2015 8:01 AM Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, a Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart FailureOctober 27, 2015 8:01 AM Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart FailureOctober 27, 2015 8:00 AM